This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Niagen Bioscience (NAGE) and AC Immune SA (ACIU)

Tipranks - Tipranks - Thu Jul 2, 5:42AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT), Niagen Bioscience (NAGE) and AC Immune SA (ACIU).

4th of July Sale - 70% Off

Sarepta Therapeutics (SRPT)

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics, with a price target of $5.00. The company’s shares closed last Tuesday at $17.97.

According to TipRanks.com, Kapoor is a 5-star analyst with an average return of 14.8% and a 47.9% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Kyverna Therapeutics, Inc., BioMarin Pharmaceutical, and Crispr Therapeutics AG. ;'>

Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $23.00.

See today’s best-performing stocks on TipRanks >>

Niagen Bioscience (NAGE)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Niagen Bioscience, with a price target of $11.00. The company’s shares closed last Tuesday at $3.19, close to its 52-week low of $2.31.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 25.8% and a 63.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and MapLight Therapeutics, Inc. ;'>

Niagen Bioscience has an analyst consensus of Strong Buy, with a price target consensus of $11.25, representing a 243.0% upside. In a report released yesterday, TipRanks – PerPlexity also upgraded the stock to Buy with a $4.00 price target.

AC Immune SA (ACIU)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on AC Immune SA today and set a price target of $12.00. The company’s shares closed last Tuesday at $2.38, close to its 52-week low of $1.95.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 24.9% and a 54.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Madrigal Pharmaceuticals. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AC Immune SA with a $12.00 average price target.

Read More on SRPT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).